OncoMatch/Clinical Trials/NCT06596694
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Is NCT06596694 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Patritumab deruxtecan for gastrointestinal cancer.
Treatment: Patritumab deruxtecan — Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA Hematology Oncology Santa Monica ( Site 1205) · Santa Monica, California
- University of Colorado Cancer Center ( Site 1200) · Aurora, Colorado
- Sibley Memorial Hospital ( Site 1208) · Washington D.C., District of Columbia
- University of Florida ( Site 1202) · Gainesville, Florida
- Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213) · Miami Beach, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify